Aldeyra Reports Positive Top-line Results From Phase 3 INVIGORATE Trial - Quick Facts

Aldeyra Therapeutics, Inc. (ALDX) reported positive top-line results from the phase 3 INVIGORATE clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug, in patients with allergic conjunctivitis. The company said the clinical trial successfully achieved statistical significance for the primary endpoint and all secondary endpoints.

Aldeyra plans to meet with the FDA in the second half of 2021 to discuss the INVIGORATE results and the potential submission of a New Drug Application.

Shares of Aldeyra Therapeutics were up 25% in pre-market trade on Tuesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
When Can We Expect Starlink to Go Public? This question got an answer from Tesla and SpaceX CEO Elon Musk, who said he will only publicly list SpaceX's satellite internet service Starlink when its revenue is more predictable. Musk was responding to a users tweet, "Any thoughts on Starlink IPO we would love to invest in the future. Any thoughts on first dibs for Tesla retail investors?" John David McAfee, who founded the antivirus software company McAfee Associates, has been found dead in a prison cell in Spain shortly after a Spanish court agreed to extradite him to the US to face tax evasion charges, multiple reports said. He was arrested in Spain in October 2020 after being accused of failing to file tax returns for four years. While reporting financial results for the first quarter of fiscal 2022 on Thursday, drugstore chain Rite Aid Corp. (RAD) initiated its adjusted loss and total revenue guidance for the full-year 2022, below analysts' estimates. For fiscal 2022, the company now projects an adjusted loss in a range...
Follow RTT